Ocrevus Mechanism of Action: How It Targets B Cells

Ocrevus (ocrelizumab) works by selectively destroying B cells, a type of white blood cell that plays a central role in the immune attacks behind multiple sclerosis. It does this by binding to a protein called CD20 on the surface of B cells, flagging them for elimination by the body’s own immune defenses. But the story beneath that one-sentence explanation is richer than most patients hear at their infusion appointments. Ocrelizumab’s effects extend beyond simple B-cell killing, reaching into T-cell behavior, antibody levels, and even the brain’s own immune environment.

Why B Cells Matter in Multiple Sclerosis

For decades, MS was understood mainly as a T-cell disease. T cells were the villains crossing the blood-brain barrier and attacking myelin, the insulating sheath around nerve fibers. B cells were considered supporting players at best. That picture changed dramatically when clinical trials of B-cell-depleting therapies produced unexpectedly strong results, forcing researchers to reconsider how much B cells contribute.

B cells do more in MS than just make antibodies. They act as antigen-presenting cells, essentially showing fragments of proteins to T cells and activating them. They also pump out inflammatory signaling molecules that help create a hostile environment inside the central nervous system, drawing in other immune cells and sustaining the cycle of damage.¹ Beyond that, B cells can form organized clusters of immune tissue in the meninges (the membranes surrounding the brain), produce neurotoxic factors, and secrete cytokines that drive damage independently of antibody production.² Removing B cells disrupts all of these functions at once, which helps explain why the clinical benefits of ocrelizumab go beyond what you’d expect from simply lowering antibody levels.

How Ocrelizumab Targets and Kills B Cells

Ocrelizumab is a humanized monoclonal antibody, meaning it was engineered from a mouse antibody but modified so that most of its structure looks human to the immune system. It binds to a specific spot on the CD20 protein, which sits on the surface of B cells from their early development stages through maturity but disappears once they become antibody-secreting plasma cells. That distinction matters: because plasma cells lack CD20, ocrelizumab depletes the B-cell populations driving inflammation while largely sparing the cells that maintain long-lived protective antibodies.

Once ocrelizumab latches onto CD20, the B cell is eliminated primarily through a process called antibody-dependent cellular cytotoxicity, or ADCC. In ADCC, natural killer cells and other immune effectors recognize the antibody coating the B cell, latch on, and destroy it.³ This is ocrelizumab’s dominant killing pathway, and it distinguishes the drug from some other anti-CD20 antibodies that rely more heavily on complement-dependent cytotoxicity (CDC), a mechanism where blood proteins punch holes directly in the target cell’s membrane.

That said, the separation between these pathways is not absolute. Lab work has shown that ocrelizumab can trigger complement activation, measured by elevated levels of terminal complement complex, even though ADCC is its primary tool.⁴ Interestingly, rituximab, the older anti-CD20 antibody that preceded ocrelizumab, did not trigger significant complement activation in the same experiments. The clinical significance of this complement activity is still being worked out, but it suggests that even antibodies classified as “ADCC-dominant” have more nuanced biology than their labels imply.

Another mechanism worth noting is antibody-dependent cellular phagocytosis, where macrophages essentially eat the antibody-coated B cell. Research on CD20 antibodies in a cancer model found that phagocytosis was more than ten-fold more efficient per effector cell than ADCC.⁵ Whether the same ratio holds in MS patients is unclear, but it highlights that ADCC may not be the whole story even within its own category of cell-mediated killing.

Effects That Reach Beyond B Cells

One of the more surprising findings about ocrelizumab is that it doesn’t only affect B cells. Small subsets of T cells also carry low levels of CD20 on their surface, and ocrelizumab depletes these “CD20-dim” T cells directly. Research in people with primary progressive MS found that circulating CD20-dim CD4+ and CD20-dim CD8+ T cells were significantly reduced after treatment, and in the cerebrospinal fluid, B cells and CD20-dim memory CD4+ T cells were lower as well.⁶ The researchers concluded that these CD20-dim T cells likely contribute to ocrelizumab’s therapeutic effect, particularly in progressive disease.

Even T cells that don’t carry CD20 are affected indirectly. Immune profiling of patients with early relapsing-remitting MS showed that ocrelizumab treatment shifted the balance of CD4+ T cells: naive CD4+ T cells increased, while effector memory T cells expressing markers associated with migration into the brain decreased.⁷ A separate study found that ocrelizumab reduced the expression of activation and migratory markers on CD8+ T cells and natural killer cells, lowering their ability to kill targets in laboratory tests. The same study noted a selective reduction in CD8+ T-cell proliferation in response to Epstein-Barr virus peptides.⁸

That last point is particularly interesting because Epstein-Barr virus has become a leading suspect as a trigger for MS. If ocrelizumab dials down the T-cell response to EBV, it could be dampening an immune overreaction that contributes to the disease. But it could also theoretically weaken surveillance of the virus itself. Researchers are still teasing apart whether this is a net positive or a trade-off.

Limited Access to the Central Nervous System

Ocrelizumab is a large antibody molecule, and like other monoclonal antibodies, it does not easily cross the blood-brain barrier. Evidence suggests that it penetrates the cerebrospinal fluid poorly, making direct coating of B cells inside the brain unlikely.⁹ This raises a legitimate question: if the drug can’t get into the brain efficiently, how does it help with progressive MS, where much of the damage is thought to happen behind the blood-brain barrier?

Part of the answer is that depleting B cells in the blood reduces the supply of new inflammatory cells migrating into the brain. It also lowers the circulating levels of inflammatory cytokines that can signal across the barrier. But for immune activity already established within the central nervous system, such as organized immune clusters in the meninges, ocrelizumab’s reach appears limited. A pilot study using advanced MRI to track meningeal inflammation found that ocrelizumab did not significantly reduce it over one year, though it did decrease the humoral response to Epstein-Barr virus, likely by reducing the B-cell population overall.¹⁰ A second pilot study confirmed minimal changes in both the number and volume of leptomeningeal enhancement foci after a year of treatment.¹¹

This is one reason many neurologists believe that starting ocrelizumab earlier in the disease course, before extensive compartmentalized inflammation has established itself in the brain, may yield better long-term outcomes than waiting until progression is advanced. The drug is very good at cutting off the supply line, less good at clearing out what’s already behind the walls.

How B Cells Come Back After Treatment

Ocrelizumab is given as an intravenous infusion every six months, and between doses, the immune system gradually begins to rebuild its B-cell population. The pattern of reconstitution is not random. The first B cells to reappear are immature, transitional, and regulatory types, including a subset called CD1d+ CD5+ regulatory B cells.¹² Memory B cells, the type most implicated in driving MS relapses, are much slower to return. This reconstitution order is probably part of why the drug works: it preferentially depletes the problematic mature and memory B cells while allowing the immune system to regenerate with a “cleaner” population.

At the standard six-month dosing interval, only about three to five percent of patients have recovered even a minimal B-cell count. By nine months after the last infusion, roughly half have meaningful B-cell repopulation, and by twelve months, about 85 to 90 percent have recovered.¹³ However, cumulative exposure to ocrelizumab appears to make it harder for memory B cells specifically to bounce back. One study found that higher cumulative doses were associated with persistent memory B-cell depletion, even after accounting for the time since the last infusion.¹⁴

This has practical implications. Some clinicians have explored extended interval dosing, stretching the time between infusions beyond six months once B cells are fully depleted. Early data suggest that extending the interval allows more transitional, naive, and regulatory B cells to repopulate without a parallel increase in memory B cells or plasmablasts, and without compromising clinical efficacy.¹⁵ The appeal is obvious: potentially preserving more immune function (particularly for vaccine responses and infection defense) while maintaining disease control.

What Happens to Your Antibody Levels Over Time

Because ocrelizumab wipes out B cells, and B cells are the precursors to antibody-producing plasma cells, there’s a natural concern about what happens to immunoglobulin levels with long-term use. The answer depends on which immunoglobulin you’re looking at and how long treatment continues.

IgM levels tend to drop early and substantially. IgG levels decline more slowly, and one real-world cohort study found that IgG decreased over the first few years but then stabilized after year three.¹⁶ IgA levels tend to remain relatively stable. A systematic review of clinical trial and real-world data confirmed that IgG declines were more pronounced in controlled trial settings, while real-world evidence showed more modest reductions.¹⁷

The practical question most patients care about is whether falling immunoglobulin levels translate into more infections. A longitudinal study tracking IgG alongside infection episodes found that patients who experienced an infection that needed treatment had significantly lower IgG levels before the event compared to those who stayed infection-free.¹⁸ Lower pre-infection IgG was independently associated with higher subsequent infection risk. The real-world cohort study mentioned above, however, found no significant association between immunoglobulin levels and severe infections over long-term follow-up.¹⁹ The discrepancy likely reflects differences in patient populations and follow-up periods, but the takeaway for patients is that periodic immunoglobulin monitoring is sensible, especially after years of treatment.

Vaccine Responses on Ocrelizumab

The COVID-19 pandemic brought this issue into sharp focus. Ocrelizumab substantially impairs the antibody response to vaccination, which makes sense given that it depletes the B cells needed to produce those antibodies. In one study of COVID-19 vaccination in ocrelizumab-treated patients, many had a negative antibody response. But here’s the encouraging part: every single one of those patients with a negative antibody result still mounted a positive T-cell response.²⁰

T-cell immunity is not a perfect substitute for antibodies, but it provides meaningful protection, particularly against severe disease. For patients on ocrelizumab, timing vaccinations to coincide with the end of the dosing cycle, when some B-cell recovery has begun, may improve the antibody response. This is one area where extended interval dosing could have a secondary benefit by allowing a wider window of partial B-cell recovery.

Genetics Can Change How Well It Works

Not everyone responds to ocrelizumab identically, and part of the variation may come down to genetics. ADCC, ocrelizumab’s main killing mechanism, depends on natural killer cells binding to the antibody through a receptor called FcγRIIIa. A common genetic variant in the gene encoding this receptor, known as the FCGR3A V158F polymorphism, affects how tightly the receptor grips the antibody. Researchers found that this polymorphism influenced how quickly B cells came back between doses: patients with certain variants had different repopulation kinetics, with longer infusion intervals interacting with the polymorphism to modify outcomes.²¹

This kind of pharmacogenomic variation could eventually inform personalized dosing strategies. A patient whose natural killer cells bind ocrelizumab tightly might maintain B-cell depletion longer on extended intervals, while someone with weaker receptor binding might need the standard six-month cycle. The research is still early, but it moves the field toward more tailored treatment rather than one-size-fits-all scheduling.

How Clinicians Track the Drug’s Deeper Effects

Counting B cells in the blood tells you whether ocrelizumab is doing its most obvious job, but researchers have been looking at subtler markers to understand whether the drug is also limiting the nerve damage that drives long-term disability. Neurofilament light chain is a protein released when nerve fibers are injured, and its levels in the blood serve as a proxy for ongoing neurodegeneration. A real-world study found that ocrelizumab reduced average neurofilament light chain levels from about 12.7 pg/mL at baseline to about 6.5 pg/mL after twelve months, a significant drop that was detectable as early as three months after the first infusion.²² Review-level evidence also points to reductions in brain atrophy rates and improvements in cognitive function and fatigue that appear partially independent of the drug’s suppression of visible inflammatory lesions.²³

These findings suggest that ocrelizumab may have neuroprotective effects beyond what you’d predict from inflammation control alone. Whether that protection comes from eliminating B-cell-derived neurotoxic factors, calming T-cell activity, or some combination is still under investigation. But for patients, the practical implication is reassuring: the drug appears to be doing more than just preventing relapses.

Antidrug Antibodies and Drug Levels

A small number of patients develop antibodies against ocrelizumab itself, which can reduce the drug’s effectiveness. In one study measuring drug concentrations and antidrug antibodies, about 6 percent of patients had detectable antidrug antibodies, and those patients had correspondingly low ocrelizumab concentrations in their blood alongside early B-cell repopulation.²⁴ This is relatively uncommon, partly because ocrelizumab’s humanized structure makes it less likely to trigger an immune reaction than older, more mouse-derived antibodies. Still, for patients who experience unexplained B-cell recovery between doses, measuring drug levels and checking for antidrug antibodies can help explain what’s happening and guide next steps.

How Ocrelizumab Compares to Other Anti-CD20 Antibodies

Ocrelizumab is not the only anti-CD20 therapy used in MS. Rituximab has been used off-label for years, ofatumumab is now approved as a subcutaneous injection, and ublituximab was recently approved as well. All of them deplete B cells by targeting CD20, but structural differences between the molecules lead to different balances of killing mechanisms and different tolerability profiles.²⁵

Ocrelizumab leans heavily on ADCC; rituximab engages more complement-dependent killing; ofatumumab, given subcutaneously, may offer improved tolerability partly due to its route of administration. The exact binding site on CD20 also differs among these antibodies, though current evidence suggests that the specific epitope targeted does not dramatically change clinical activity or tolerability. The most consequential differences seem to come from the killing mechanism and how the drug is delivered, not from precisely where on the CD20 molecule the antibody parks itself.

For patients, the practical takeaway from these comparisons is that anti-CD20 therapy is not a single option but a class with meaningful variation. Clinicians choosing between these agents weigh factors like infusion-related reaction rates, insurance coverage, subcutaneous versus intravenous convenience, and emerging data on long-term immunoglobulin preservation. The mechanistic differences are real, but they manifest most clearly in tolerability rather than in raw efficacy, where all four antibodies have shown strong results against relapsing MS.